CXCR3 and neoplasm: In these cases, CXCR3 antagonists ‎could be ‎used to block the tumor’s ability to use CXCL10 for immunosuppression, while in other ‎‎cases care must be taken to preserve the positive immune-activating effects of CXCL10.